the current guidelines and therapies for tp53-mutated mds and aml
Published 1 month ago • 90 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
3:00
apr-246 in tp53 mutated mds and aml
-
1:23
immunological impact of tp53 in mds
-
19:30
mechanisms of gene regulation by chromatin adaptor proteins
-
5:36
what is mxdr and how can it benefit your organization?
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
1:13
targeting p53 in mds
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
4:38
soho 2021 highlights: ‘targeting p53 in mds’
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
1:18
the mechanism of action of anti-cd47 antibodies & where these may fit in the mds treatment landscape
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
1:34
perspectives on the management of low and high-risk mds
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml